Latest Module
Making sense of SGLT-2 inhibitors in daily practice – 2026 Clinical update of CRM therapy
This practice-orientated review focuses on the safe and effective early use of SGLT-2 inhibitors across the continuum of T2DM
What is new? Advanced Technologies and Treatment for Diabetes (ATTD)
Interpreting advances in AI, diabetes screening, hypoglycaemic unawareness and glycaemic risk in the care T1 & T2DM patients
The ethical balance between AI and human Intelligence in clinical practice (Clinical lunch chat – On demand)
Dr David Roytowski brings a practitioner’s perspective to the ethics and application of AI


